It is in the cards, and thus should come as no big surprise, that the pharmaceutical company Biogen is very likely to receive the European thumbs-down for its Alzheimer's drug, Aduhelm (aducanumab).
The formal rejection is expected in December, when the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) holds its next monthly meeting.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.